Groups of services delivered by Brazilian branchless banking and respective network integration models

Over the last decade, Brazil has pioneered an innovative model of branchless banking, known as correspondent banking, involving distribution partnership between banks, several kinds of retailers and a variety of other participants, which have allowed an unprecedented growth in bank outreach and became a reference worldwide. However, despite the extensive number of studies recently developed focusing on Brazilian branchless banking, there exists a clear research gap in the literature. It is still necessary to identify the different business configurations involving network integration through which the branchless banking channel can be structured, as well as the way they relate to the range of bank services delivered. Given this gap, our objective is to investigate the relationship between network integration models and services delivered through the branchless banking channel. Based on twenty interviews with managers involved with the correspondent banking business and data collected on almost 300 correspondent locations, our research is developed in two steps. First, we created a qualitative taxonomy through which we identified three classes of network integration models. Second, we performed a cluster analysis to explain the groups of financial services that fit each model. By contextualizing correspondents' network integration processes through the lens of transaction costs economics, our results suggest that the more suited to deliver social-oriented, "pro-poor'' services the channel is, the more it is controlled by banks. This research offers contributions to managers and policy makers interested in understanding better how different correspondent banking configurations are related with specific portfolios of services. Researchers interested in the subject of branchless banking can also benefit from the taxonomy presented and the transaction costs analysis of this kind of banking channel, which has been adopted in a number of developing countries all over the world now. (C) 2011 Elsevier B.V. All rights reserved.

Importância das cooperativas de crédito para fornecedores de cana-de-açúcar: um estudo de caso

No presente trabalho analisa-se a importância das cooperativas no mercado de crédito rural do Brasil, com foco na visão de quem demanda empréstimos. Para tanto, realizou-se um estudo de caso referente à Cooperativa de Crédito Rural dos Fornecedores de Cana e Agropecuaristas da Região de Piracicaba (Cocrefocapi). O objetivo principal é mostrar a importância da Cocrefocapi no financiamento dos fornecedores de cana de Piracicaba, a partir da análise da influência de vários fatores presentes na decisão dos cooperados em escolher esta instituição como principal financiadora. Assim, foram elaborados e testados dois modelos econométricos de resposta qualitativa, além de várias análises descritivas. Os resultados mostram que o tamanho da terra é um fator que deve ser considerado ao se analisar a demanda por crédito agrícola. Além disso, não existe evidência econométrica que mostre que os associados com maior participação no capital institucional da Cocrefocapi tenham maiores incentivos para tomar empréstimos junto à cooperativa. Por outro lado, embora os fornecedores que tomaram empréstimos na Cocrefocapi a tenham escolhido principalmente por menores custos de transação, os resultados indicam que muitas destas pessoas tomaram empréstimos em outras instituições, pois, além de produzirem cana, conduzem outras atividades econômicas que não são financiadas pela Cocrefocapi.

Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system

Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system Objectives: To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). Methods: A discrete event simulation model seas built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY)) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. Results: The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years, were R$ 10,850,185, R$ 14,836,265 and R$ 14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R$ 3,874 and R$ 3,996, respectively. The BIM estimated cumulative savings of R$ 417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. Conclusion: From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon.